Table 1:
Patient Characteristics
| (n=16) | |
|---|---|
| Age | |
| median age (range) | 54 (30-68) |
| Sex, n (%) | |
| Female | 4 (25) |
| Male | 12 (75) |
| Diagnosis, n (%) | |
| Acute myeloid leukemia | 6 (38) |
| Non Hodgkin Lymphoma | 4 (25) |
| Multiple Myeloma | 2 (13) |
| Hodgkin lymphoma | 1 (6) |
| Chronic Lymphocytic Leukemia | 1 (6) |
| Myelofibrosis | 1 (6) |
| MDS/MPN (CMML vs CML) | 1 (6) |
| Allo-Transplant Overall Disease Risk Index, n (%) [12] | |
| Low | 2 (13) |
| Intermediate | 9 (56) |
| High | 5 (31) |
| Very High | 0 (0) |
| CMV status, n (%) | |
| Recipient or donor positive | 12 (75) |
| Recipient and donor negative | 4 (25) |
| Conditioning Regimens, n (%) | |
| Fludarabine melphalan alemtuzumab | 12 (75) |
| Busulfan, fludarabine, antithymocyte globulin | 3 (19) |
| Busulfan, cyclophosphamide, antithymocyte globulin | 1 (6) |
| GvHD prophylaxis at the time of study DLI infusion, n (%) | |
| Mycophenolate Mofetil alone | 7 (44) |
| Prednisone alone | 2 (12) |
| Tacrolimus alone | 1 (6) |
| Two of Mycophenolate Mofetil, prednisone and tacrolimus | 3 (19) |
| None | 3 (19) |